CME Advisory Committee
It is the policy of the University of Florida College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all programs it provides. In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Integrity and Independence in Accredited Continuing Education, the University of Florida College of Medicine is required to disclose to the activity audience the relevant financial relationships of all persons involved in the selection, development, and presentation of CME content. Persons who refuse or fail to disclose conflicts of interest are disqualified from participating in the CME activity.
The CME Advisory Committee, which is a multidisciplinary group with representation from both the academic faculty and community, meets every month to review and approve program applications. Because Advisory Committee members are in a position to influence content of CME activities, each member is required to disclose financial relationships which may create a conflict of interest.
All relevant financial relationships listed have been mitigated.
Relevant financial relationships for CME Advisory Committee members appear below.
The following Advisory Committee members have an affiliation/financial interest in the following areas:
- Alan B. Miller, MD — Consultant: Abbvie, CV-RX, Syneos and Iqvia
- Adolfo Ramirez-Zamora, MD — Consultant: Medtronic Inc and Signant Health
- Anita Wokhlu, MD — Research Support: Abbvie and Bayer; Lab Reader for Artivion Core lab (previously PROACT CryoLife)
The following Advisory Committee members have no relevant financial relationships to disclose:
- Reem Abu-Rustum, MD
- Carlos Arango, MD
- Petar Breitinger, PA-C, MPAS
- Si Chen, MD
- Parta Hatamizadeh, MD
- Colleen Kalynych, MD
- Jay Khadpe, MD
- Raafat Makary, MD, PhD
- Shahla Masood, MD
- Stephanie McCormick, PharmD
- Emely McKitrick
- Giles Peek, MD
- Teresa Roane, PharmD
- Eric Rosenberg, MD, MSPH, FACP
- Carla Zingariello, DO
This page was last reviewed on 5/24/23.
View previous disclosures from 4/27/18 – 8/31/18
View previous disclosures from 9/1/18 – 3/19/19
View previous disclosures from 3/20/19 – 2/16/21